CIK 0001682852 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | |
|---|---|---|
| Revenue (USD) | 1.9 B | 19.3 B |
| Net income (USD) | -2.8 B | 8.4 B |
| Diluted EPS (USD/shares) | -7.26 | 20.12 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | 4 | PRIMARY DOCUMENT | 2026-10-14 |
| 2026-10-15 | 144 | 144 | |
| 2026-10-14 | 144 | 144 | |
| 2026-10-07 | 4 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-10-05 | 3 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-09-30 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-09-30 |
| 2026-09-16 | 4 | PRIMARY DOCUMENT | 2026-09-14 |
| 2026-09-15 | 144 | 144 | |
| 2026-09-14 | 4 | PRIMARY DOCUMENT | 2026-09-10 |
| 2026-09-14 | 144 | 144 | |
| 2026-09-10 | 144 | 144 | |
| 2026-09-08 | 4 | PRIMARY DOCUMENT | 2026-09-04 |
| 2026-09-08 | 4 | PRIMARY DOCUMENT | 2026-09-04 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-03 | 4 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-09-01 | 8-K | 8-K items 1.01,2.03,3.02,8.01,9.01 | 2026-08-27 |
| 2026-09-01 | 144 | 144 | |
| 2026-08-31 | 4 | PRIMARY DOCUMENT | 2026-08-27 |
| 2026-08-31 | 4 | PRIMARY DOCUMENT | 2026-08-27 |
| 2026-08-31 | 4 | PRIMARY DOCUMENT | 2026-08-27 |
| 2026-08-12 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-07 | 4 | PRIMARY DOCUMENT | 2026-08-05 |
| 2026-08-06 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-05 | 144 | 144 |
Forms on file (last 1,000): 4 676, 144 163, 8-K 60, 10-Q 17, SC 13G/A 14, 3 11, SCHEDULE 13G/A 8, DEFA14A 7. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MRNA (0.002 USD), /gw/filings/filings?ticker=MRNA&form=8-K, /gw/filings/facts?ticker=MRNA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange